Canaquest Medical Corporation · OTC:CANQF
Canaquest Medical — Investor Presentation (December 2021)
19 slides from Canaquest Medical's investor presentation, Dec 30, 2021
Slide 1: Corporate Presentation
Corporate Presentation December 2021
Slide 2: Current Challenge in Prescribing Cannabis
Current Challenge in Prescribing Cannabis | Limited science behind “medical” cannabis products • Trial and error - physicians have a difficult time prescribing precise doses • Low bioavailability and toxicity - many products require large ingestible doses with low efficacy (6%-10%) and possible toxi
Slide 3: Two Master Formulations
Two Master Formulations |Medical cannabis products used as formulation bases for Rx drug candidates Mentanine® Mentabinol® Base formulation for Rx CQ-001 Base formulation for Rx CQ-002 • Pharmaceutical Grade CBD Omega-3 proprietary • Pharmaceutical Grade THC + L-Theanine proprietary formulation form
Slide 4: The Scientific Difference: CBD vs. Mentanine
The Scientific Difference CBD vs. Mentanine® Pure Cannabidiol Scientifically developed proprietary formula CBD…… • Does not effectively reach the section of the brain that regulates emotion. Thus, CBD alone is not effective for treating mental health ailments. • Has nominal effect on neurological co
Slide 5: Unique Formulation. Not a Generic Knockoff
Unique Formulation. Not a Generic Knockoff | Comparison with similar FDA approved product Epidiolex® Double acting formula – on the center nervous system (the brain) and Acts on the endocannabinoid system, requiring high dosage to reach endocannabinoid system desired results at the brain level Activ
Slide 6: Pre-clinical Trials — Mentanine
Pre-clinical Trials — Mentanine® | Pharmaceutical Grade CBD Omega-3 formulation Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience Oct 2020 C O N F I D E N T I A L & P R O P R I E TA R Y 6
Slide 7: The Scientific Difference: THC vs. Mentabinol
The Scientific Difference THC vs. Mentabinol® Pure THC Scientifically developed proprietary formula THC can cause…… • Memory impairment & possible long-term cognitive side effects • Depression-like and schizophrenia-related symptoms • Anxiety and hyperactive activity • Schizophrenia due to gene vuln
Slide 8: Pre-clinical Trials — Mentabinol
Pre-clinical Trials — Mentabinol® | Pharmaceutical Grade THC + L-Theanine formulation • Scientifically developed by CanaQuest’s lead scientist and university-based experts in neuroscience • Pre-clinical trial results – published in peer-reviewed journals December 2020 July 2021 C O N F I D E N T I A
Slide 9: Steps to US-FDA and Health Canada Approvals (CQ-001 Rx)
Steps to US-FDA and Heath Canada Approvals |Obtaining Drug Identification Numbers DIN for CQ-001 Rx Targeting Rx drug candidate for two epilepsy rare conditions Dravet Syndrome and Lennox-Gastaut Syndrome COMPLETED STEPS NEXT STEPS TO OBTAIN A DIN FOR CQ-001 Rx – Mentanine® base formulation CanaQues
Slide 10: Steps to US-FDA and Health Canada Approvals (CQ-002 Rx)
Steps to US-FDA and Heath Canada Approvals | Obtaining Drug Identification Numbers DIN for CQ-002 Rx Targeting Rx candidate as a neurological drug COMPLETED STEPS FOR CQ-002 Rx NEXT STEPS TO OBTAIN A DIN FOR CQ-002 Rx – Mentabinol® base formulation CanaQuest Scientific Partnership Network Research a
Slide 11: Advanced Rx Drug Pipeline
Advanced Rx Drug Pipeline | Preapproved human trials for CQ-001 Rx and CQ-002 Rx candidates TRIAL TRIAL TIME TO OBTAIN DIN & DATE DURATION Rx APPROVALS Therapeutic Dr Didier Jutras- Q1 2022 Phase 1: After DIN is obtained for CQ-001 Rx, Cannabis Aswad approval will be sought to add this early phase t
Slide 12: Pipeline for Future Rx Drugs
Pipeline for Future Rx Drugs | Scientific Research Project Description Specialists Status Neurological Research and pre-clinical Dr Steven Laviolette + team of Ongoing trials; new formulated 13 scientists Conditions & product development with Mental Health synergistic botanicals Focus on anxiety, PT
Slide 13: Partnerships - Manufacturing
Partnerships - Manufacturing | Manufacturing ready to start Canada USA Launching Mentanine® and Mentabinol® in Q1 2022 Launching Mentanine® in January 2022 PurCann Pharma, subsidiary of SiliCycle Inc. CBD - GMP Processor, California (powders, liquids) ▪ Non-Rx: signed non-exclusive agreement to prod
Slide 14: Partnerships - Distribution
Partnerships - Distribution | Distribution network in place Canada USA PurCann Pharma, subsidiary of SiliCycle Inc. Dr Rick Goulding (MD), Florida - American Medical Association ▪ Non-exclusive distribution across Canada Mentanine® distribution in the US ▪ Specialized in commercialization of cannabi
Slide 15: Scientific Partners & Regulatory Advisors
Scientific Partners & Regulatory Advisors Dr. Steven Laviolette, B.Sc., Ph.D., a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University, Addiction Research Group Dept. of Anatomy & Cell Biology, Dept. of Psychiatry R & D Program - 14 scientists https://www.
Slide 16: Scientific Partners & Pharmaceutical Advisor
Scientific Partners & Pharmaceutical Advisor Dr. David W.L. Ma, Ph.D. Medical Sciences, Professor, Department of Human Health and Nutritional Sciences, University of Guelph R & D Program - 5 scientists https://www.uoguelph.ca/hhns/people/dr-david-wl-ma • Previously, had faculty position in the Depar
Slide 17: Executive Team & Board of Directors
Executive Team & Board of Directors | 100+ Years of Management & Product Development Experience Richard Rusiniak, Mechanical Engineer, CEO – Director • Over 35 years of management, design and process experience; • Co-founder and former President, CFO, and CTO of Cymat Corp (TSX: CYM) with a market v
Slide 18: CanaQuest Summary
CanaQuest Summary Commercially Ready Products • Mentanine® and Mentabinol®, being launched in Canada • Mentanine® being launched in the USA Pharmaceutical Rx Drug Pipeline • Two master formulations that are pharma drug candidates targeting neurological conditions: CQ-001 Rx and CQ-002 Rx, derived fr
Slide 19: Thank you
Thank you Contact Information: Paul Ramsay, President 416.704.3040 paul@canaquest.com www.canaquest.com 19
CanaQuest Medical — Investor Presentation (December 2021) on 6ix